NF-κB-IN-11 (Compound 3i) is an inhibitor of NF-κB, effectively blocking TNF-α-induced NF-κB pathway activation and the nuclear translocation of NF-κB. It also reduces the expression levels of phospho-IKK, IκBα, and NF-κB p65. Demonstrating anti-inflammatory properties, NF-κB-IN-11 mitigates dextran sulfate sodium-induced colitis in mice and exhibits a maximum tolerated dose (MTD) exceeding 1852 mg/kg in acute toxicity assays when administered orally (p.o.) [1].